Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Armuzzi

Showing results (11-20 of 320) with videos related to

Pageof 32
Sort By:
Frontiers in Pharmacology|November 19, 2024
JAK inhibitors: an evidence-based choice of the most appropriate moleculeLuca Antonioli, Alessandro Armuzzi, Massimo C Fantini, et al.
Nature Reviews. Gastroenterology & Hepatology|February 13, 2023
The gasdermin protein family: emerging roles in gastrointestinal health and diseaseGiuseppe Privitera, Nitish Rana, Alessandro Armuzzi, et al.
Journal of Crohn'S & Colitis|March 5, 2013
Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel diseaseGiammarco Mocci, Manuela Marzo, Alfredo Papa, et al.
Nutrients|April 27, 2024
Dietary Fiber in Inflammatory Bowel Disease: Are We Ready to Change the Paradigm?Laura Loy, Lorenzo Petronio, Giacomo Marcozzi, et al.
Journal of Clinical Medicine|November 26, 2022
Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD TherapiesDaniela Pugliese, Sara Onali, Giuseppe Privitera, et al.
Mini Reviews in Medicinal Chemistry|July 18, 2006
Biological therapies for inflammatory bowel disease: research drives clinicsSilvio Danese, Stefano Semeraro, Alessandro Armuzzi, et al.
Frontiers in Cellular and Infection Microbiology|February 3, 2022
Novel Insights Into the Interactions Between the Gut Microbiome, Inflammasomes, and Gasdermins During Colorectal CancerGiuseppe Privitera, Nitish Rana, Franco Scaldaferri, et al.
Clinical Immunology (Orlando, Fla.)|December 31, 2021
Therapeutic agents affecting the immune system and drug-induced inflammatory bowel disease (IBD): A review on etiological and pathogenetic aspectsRachele Del Sordo, Vassilios Lougaris, Gabrio Bassotti, et al.
International Journal of Molecular Sciences|February 25, 2023
Cytokines in Spondyloarthritis and Inflammatory Bowel Diseases: From Pathogenesis to Therapeutic ImplicationsCarla Felice, Arianna Dal Buono, Roberto Gabbiadini, et al.
Minerva Gastroenterologica E Dietologica|October 25, 2019
Therapeutic drug monitoring with vedolizumab in inflammatory bowel diseaseDaniela Pugliese, Giuseppe Privitera, Fabrizio Pizzolante, et al.
Pageof 32

Showing results (11-20 of 320) with videos related to

Sort By:
Pageof 32
Frontiers in Pharmacology|November 19, 2024
JAK inhibitors: an evidence-based choice of the most appropriate moleculeLuca Antonioli, Alessandro Armuzzi, Massimo C Fantini, et al.
Nature Reviews. Gastroenterology & Hepatology|February 13, 2023
The gasdermin protein family: emerging roles in gastrointestinal health and diseaseGiuseppe Privitera, Nitish Rana, Alessandro Armuzzi, et al.
Journal of Crohn'S & Colitis|March 5, 2013
Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel diseaseGiammarco Mocci, Manuela Marzo, Alfredo Papa, et al.
Nutrients|April 27, 2024
Dietary Fiber in Inflammatory Bowel Disease: Are We Ready to Change the Paradigm?Laura Loy, Lorenzo Petronio, Giacomo Marcozzi, et al.
Journal of Clinical Medicine|November 26, 2022
Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD TherapiesDaniela Pugliese, Sara Onali, Giuseppe Privitera, et al.
Mini Reviews in Medicinal Chemistry|July 18, 2006
Biological therapies for inflammatory bowel disease: research drives clinicsSilvio Danese, Stefano Semeraro, Alessandro Armuzzi, et al.
Frontiers in Cellular and Infection Microbiology|February 3, 2022
Novel Insights Into the Interactions Between the Gut Microbiome, Inflammasomes, and Gasdermins During Colorectal CancerGiuseppe Privitera, Nitish Rana, Franco Scaldaferri, et al.
Clinical Immunology (Orlando, Fla.)|December 31, 2021
Therapeutic agents affecting the immune system and drug-induced inflammatory bowel disease (IBD): A review on etiological and pathogenetic aspectsRachele Del Sordo, Vassilios Lougaris, Gabrio Bassotti, et al.
International Journal of Molecular Sciences|February 25, 2023
Cytokines in Spondyloarthritis and Inflammatory Bowel Diseases: From Pathogenesis to Therapeutic ImplicationsCarla Felice, Arianna Dal Buono, Roberto Gabbiadini, et al.
Minerva Gastroenterologica E Dietologica|October 25, 2019
Therapeutic drug monitoring with vedolizumab in inflammatory bowel diseaseDaniela Pugliese, Giuseppe Privitera, Fabrizio Pizzolante, et al.
Pageof 32